Company intelligence / Profile preview

Fairtility

Ownership: Private
Employees: ~45
Development stage: Commercial

Overview

Fairtility’s CHLOE™ platform has demonstrated high accuracy in predicting blastocyst formation (96%) and implantation potential (73%), outperforming manual and other automated methods. The technology has been validated on over 50,000 embryos across multiple clinics worldwide and received CE mark approval for commercial use in Europe. Clinical studies are ongoing with global fertility clinic partners.

Therapeutic areas: Women's Health
Modalities: DeviceNon-pharmacological therapy (AI-based clinical decision support system for IVF)
Industry: Digital Health Medical Devices

Partnerships

Collaborations with fertility clinics globally for clinical validation and research studies

Beyond the preview

Go deeper on Fairtility.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fairtility.

Explore the full profile